Ya'ar Bar Sapir, Pintel Noam, Abd Alghne Hesen, Khattib Hamdan, Avni Dorit
Department of Natural Compound, Nutrition, and Health, MIGAL, Kiryat Shmona, Israel.
Tel-Hai College Department of Biotechnology, Kiryat Shmona, Israel.
Front Cardiovasc Med. 2023 Aug 7;10:1224743. doi: 10.3389/fcvm.2023.1224743. eCollection 2023.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide and Inflammation plays a critical role in the development of CVD. Despite considerable progress in understanding the underlying mechanisms and various treatment options available, significant gaps in therapy necessitate the identification of novel therapeutic targets. Sphingolipids are a family of lipids that have gained attention in recent years as important players in CVDs and the inflammatory processes that underlie their development. As preclinical studies have shown that targeting sphingolipids can modulate inflammation and ameliorate CVDs, targeting sphingolipids has emerged as a promising therapeutic strategy. This review discusses the current understanding of sphingolipids' involvement in inflammation and cardiovascular diseases, the existing therapeutic approaches and gaps in therapy, and explores the potential of sphingolipids-based drugs as a future avenue for CVD treatment.
心血管疾病（CVDs）是全球发病和死亡的主要原因，炎症在心血管疾病的发展中起关键作用。尽管在理解潜在机制和现有各种治疗选择方面取得了相当大的进展，但治疗方面的重大差距仍需要确定新的治疗靶点。鞘脂是一类脂质，近年来作为心血管疾病及其发展背后炎症过程的重要参与者而受到关注。临床前研究表明，靶向鞘脂可以调节炎症并改善心血管疾病，因此靶向鞘脂已成为一种有前景的治疗策略。本文综述讨论了目前对鞘脂参与炎症和心血管疾病的理解、现有的治疗方法和治疗差距，并探讨了基于鞘脂的药物作为心血管疾病未来治疗途径的潜力。
